Mylan
FDA unanimously recommends Mylan and Biocon’s Herceptin biosimilar
July 14, 2017Manufacturing and Production, Medical Communications, Sales and Marketing Biocon, Herceptin, Mylan, biosimilar, biotech, drugs, healthcare, life sciences, pharma, pharmaceuticals
Mylan and Biocon have revealed that their biosimilar version of Roche and Genentech’s Herceptin (trastuzumab) has received unanimous recommendation from …
Gilead to launch injunction against Mylan and Actavis over HIV generics in Ireland
July 6, 2017Sales and Marketing Actavis, Gilead, HIV, Mylan, Truvada
Gilead is expected to launch injunctive action against rivals Mylan and Actavis over the allegation that they are planning to …
Investors demand resignation of Mylan executives over pay packages
June 29, 2017Sales and Marketing Heather Bresch, Mylan, epipen
As confidence in Mylan continues to fall and share prices plummet after last year’s EpiPen pricing scandal and subsequent PR …
New rival to EpiPen receives FDA approval to shake up market
June 16, 2017Medical Communications, Sales and Marketing Adamis, Mylan, Symjepi, epipen
Adamis Pharmaceuticals has revealed that it received FDA approval for its EpiPen rival to enter the market. Its product, to …
Mylan overcharged for EpiPen by $1.7 billion, new report says
June 1, 2017Sales and Marketing Mylan, epipen
More bad news for Mylan as a new report from the Department of Health and Human Services’ Office of the …
Study reveals EpiPens stay effective years after expiration date
May 10, 2017Research and Development EpiPen expiration, Mylan, Mylan scandal, epipen
The Annals of Internal Medicine has published a study that indicated that EpiPen injectors retain a medically significant proportion of …
Sanofi launches lawsuit against Mylan over “illegal business practices”
April 26, 2017Research and Development, Sales and Marketing Auvi-Q, Mylan, Sanofi, epipen, lawsuit
In a move that is sure to pile even more pressure onto Mylan after the company’s recent woes, Sanofi has …
Mylan hit with fresh lawsuit over EpiPen pricing
April 4, 2017Manufacturing and Production, Sales and Marketing Mylan, epipen, pricing
Just as it faces worldwide reports that over 80,000 of its EpiPens do not function properly and as the FDA …
FDA issues US-wide recall of Mylan’s EpiPen
April 3, 2017Medical Communications, Sales and Marketing FDA, Mylan, epipen
After recent reports of around 80,000 defective EpiPen’s across Australia, New Zealand, Japan, Norway, Denmark, Finland and Ireland, the FDA …
Mylan’s generic of best-selling GSK drug delayed by FDA
March 30, 2017Sales and Marketing Advair, GSK, Mylan
Mylan’s plan to bring its generic competitor to GSK’s best-selling respiratory drug, Advair, has hit a major snag after it …
Mylan set to close Meda US manufacturing facility
March 28, 2017Manufacturing and Production Meda, Mylan
Mylan continues to cut away Meda’s US operations to “reduce redundancy” – the latest sees Mylan closing an Illinois-based facility, …
Mylan’s pathway to launch of biosimilar to Herceptin cleared by Roche
March 13, 2017Manufacturing and Production, Sales and Marketing Genentech, Herceptin, Mylan, Roche, biosimilar
Mylan scored a big victory in its plan to launch its biosimilar to Roche’s blockbuster, Herceptin, after Roche and itself …
Pfizer plant receives FDA warning letter for contamination of medicine
March 1, 2017Manufacturing and Production Copaxone, Mylan, Pfizer, Teva, generics
The FDA has issued a warning letter to Pfizer after inspectors discovered that the plant did not protect properly against …
Mylan pays $96.5 million to settle pay-for-delay case
February 7, 2017Research and Development, Sales and Marketing Cephalon, Mylan, Teva, antitrust
Mylan has agreed to pay $96.5 million in order to settle an antitrust case. The case was related to the …
Antitrust investigation into Mylan begins over EpiPen
January 31, 2017Research and Development, Sales and Marketing Mylan, pricing
The Federal Trade Commission has submitted a request to Mylan for information as part of a preliminary investigation into whether …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
